Related Experiment Video
Updated: Dec 25, 2025
09:44
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
10.5K
Biological optimization for mediastinal lymphoma radiotherapy - a preliminary study.
Laura Ann Rechner1,2, Arezoo Modiri3, Line Bjerregaard Stick1,2
1Department of Oncology, Section of Radiotherapy, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Acta Oncologica (Stockholm, Sweden)
|March 29, 2020
Summary
This study introduces an individualized radiotherapy planning method for Hodgkin lymphoma patients. Outcome-optimized plans reduced risks of recurrence and late effects compared to standard methods.
Area of Science:
- Radiation oncology
- Medical physics
- Clinical oncology
Background:
- Current radiotherapy planning uses population-based dose constraints for organs at risk (OARs).
- Quantifying tradeoffs between target coverage and OAR doses for individual patients is challenging.
- Mediastinal Hodgkin lymphoma (HL) treatment requires balancing tumor control with risks of late toxicities.
Purpose of the Study:
- To introduce a novel radiotherapy planning approach for mediastinal HL patients.
- To simultaneously optimize tumor control and minimize mortality from late effects for individual patients.
- To develop an individualized, outcome-optimized (O-OPT) planning technique.
Main Methods:
- Retrospective analysis of 34 HL patients treated with conformal radiotherapy (3DCRT).
- Utilized published data to model recurrence and radiation-induced mortality (coronary heart disease, secondary cancers).
- Developed an in-house optimization code to create O-OPT plans, minimizing individual risks based on patient-specific doses, age, sex, and cardiac risk factors.
Main Results:
- O-OPT plans demonstrated the lowest median total risk (4.9%) compared to clinical 3DCRT (5.1%) and VMAT (7.6%) plans (without cardiac risk factors).
- O-OPT planning reduced total risk by at least 1% in 9/34 cases (no CRFs) and 11/34 cases (with CRFs) compared to clinical 3DCRT.
- O-OPT plans were often substantially different from clinically applied plans.
Conclusions:
- An individualized, outcome-optimized planning technique for Hodgkin lymphoma was successfully developed.
- This approach has the potential to improve patient outcomes by balancing tumor control and late effect risks.
- The effectiveness and specific plan differences depend on the defined risk models and prioritization.
